Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology ...Middle East

SAN FRANCISCO and SUZHOU, China, June 20, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other...

Hence then, the article about study results of sintilimab in combination with bevacizumab biosimilar ibi305 for the first line treatment of hepatocellular carcinoma published in the lancet oncology was published today ( Monday 21/06/2021 - 03:30 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology )

Also on site :

• Trump says Pam Bondi, a loyalist who oversaw Justice Department upheaval, is out as attorney general
• Ford and Toyota issue major South African car recall
• Target's 'Fabulous' Rattan Sideboard Cabinet Is Nearly 70% Off, and It's So 'Easy to Assemble'